Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Roche Holding AG (RHHVF) Receives a Buy from Kepler Capital
Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on March 21 and set a price target of ...
PMLive6d
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...
Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Morgan Stanley upgrades Zealand Pharma to Buy on ’long-term obesity potential’
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement - No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand") (NA ...